Current News

Contact | Print version | PDF version | Send article | RSS feed

KINAXO Announces Agreement with Johnson & Johnson Pharmaceutical Research & Development

15 Jan 2007 - KINAXO Biotechnologies GmbH announced that it has entered an agreement with Johnson & Johnson Pharmaceutical Research & Development (J&JPRD), a division of Janssen Pharmaceutica. Under the agreement, KINAXO will use the KinaTorTM technology to perform target selectivity analyses for selected J&JPRD small molecule compounds.
 
The KinaTorTM technology uses immobilized small molecule inhibitors to detect their protein binding partners in biological samples. Small molecule-protein interactions are identified by a combination of sophisticated affinity-based separation procedures and sensitive mass spectrometry. The KinaTorTM provides tailor-made solutions for various problems in drug development, such as the identification of previously unknown disease-relevant targets as well as off-target related toxicities.